Mycetoma
Developing safer treatments to prevent disability
We ran the world’s first clinical trial for mycetoma. Now we are working to discover and develop new treatments that can prevent disability while improving access to existing treatments.
Mycetoma is a slow-growing infection that destroys skin, muscle, and bone. Primarily affecting the feet and legs, it most likely begins after a cut or thorn prick allows fungi or bacteria from the soil to enter the body. The fungal form of the disease, known as eumycetoma, is particularly devastating and can cause severe disfigurement and disability, and result in stigma, social isolation, and mental health difficulties. While current treatments are effective when combined with surgery, they need to be taken for as long as one year, can cause side effects, and are often inaccessible to people living in remote and resource-constrained settings.
Global burden is unknown
‘This treatment helps reduce the pain and swelling, but for how long will I keep taking these pills? Is there another way to end my suffering? I wish the treatment could be shorter and more effective.’
What we have achieved
Together with partners, we successfully advocated for mycetoma to be added to the World Health Organization (WHO) list of neglected tropical diseases (NTDs) in 2016. The following year, we ran the world’s first clinical trial for fungal mycetoma – bringing a new treatment option closer to patients in under-resourced settings.
What we are doing for people living with mycetoma
While working with partners to register and expand access to existing but often unavailable drugs in mycetoma-endemic countries, our teams are continuing to advance research into new potential treatments, close knowledge gaps, and better understand the burden and impact of the disease across the ‘mycetoma belt’.
The world’s first clinical trial for mycetoma treatment. Run at the world’s only specialized centre for mycetoma, located in Khartoum, Sudan, this study tested Eisai’s fosravuconazole against the current standard treatment, itraconazole, which is expensive, must be dosed twice a day for a year, and taken with food.
Ensuring access to safe, effective, affordable treatments. We are working to expand access to treatment and to better understand the burden of mycetoma in endemic areas.
The Mycetoma Translational Platform aims to establish a suitable pathway to evaluate and advance new mycetoma drug candidates towards clinical development. DNDi and its partners at Erasmus Medical Centre and the University of Antwerp initiated the development of an in vivo model in early 2026.
Mycetoma news & resources
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.